NADH-ubiquinone oxidoreductase 18 kDa subunit Antibody

What is NDUFS4 and what role does it play in mitochondrial function?

NDUFS4 (NADH-ubiquinone oxidoreductase 18 kDa subunit) functions as an accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I). Unlike catalytic subunits, NDUFS4 is believed not to be directly involved in the enzymatic reaction but plays a critical role in complex assembly and stability. Complex I itself functions in the transfer of electrons from NADH to the respiratory chain, with ubiquinone serving as the immediate electron acceptor for the enzyme . The proper functioning of NDUFS4 is essential for maintaining mitochondrial respiration and energy production, with mutations in this subunit associated with mitochondrial disorders characterized by neurological symptoms. Understanding NDUFS4 function provides important insights into mitochondrial bioenergetics and respiratory chain disorders.

What are the common alternative names and identifiers for NDUFS4?

NDUFS4 is known by several alternative names in the scientific literature, which can sometimes cause confusion when searching databases or reviewing publications. The protein is also referred to as: Complex I-18 kDa, Complex I-AQDQ, NADH-ubiquinone oxidoreductase 18 kDa subunit, CI-18 kDa, and CI-AQDQ . When working with antibodies targeting this protein, it's important to recognize these alternative designations to ensure comprehensive literature searches and proper identification of relevant research tools. Unlike some other Complex I subunits that may have overlapping nomenclature, the 18 kDa size designation helps distinguish NDUFS4 from other complex components like NDUFS3 (a 30 kDa subunit) or NDUFA9 (a 42.5 kDa subunit) .

How does NDUFS4 differ from other Complex I subunits like NDUFS3 and NDUFA9?

NDUFS4 is functionally and structurally distinct from other Complex I subunits. Unlike NDUFS3, which is a core subunit essential for catalytic activity and assembly of Complex I , NDUFS4 serves primarily an accessory role in complex stability. NDUFS3 (30 kDa) directly participates in electron transfer and interacts with proteins like NDUFV1 and NDUFV2, highlighting its centrality in energy and signal transduction processes . NDUFA9 (42.5 kDa), another Complex I component, differs in both size and function from NDUFS4 . These distinctions are important when designing experiments targeting specific aspects of Complex I function, as targeting different subunits will provide different insights into respiratory chain assembly, function, and pathology. Researchers should consider these functional differences when selecting antibodies for specific research questions related to mitochondrial function.

What applications are NDUFS4 antibodies typically validated for?

NDUFS4 antibodies have been validated for several common research applications, with varying degrees of reliability. Based on commercially available antibodies, the most common validated applications include Western Blotting (WB) and immunohistochemistry on paraffin-embedded sections (IHC-P) . These applications represent the primary means by which researchers investigate NDUFS4 expression and localization in tissues and cell lysates. When selecting an NDUFS4 antibody, it's crucial to verify that the specific antibody has been validated for your intended application, as performance can vary significantly between applications. For instance, antibodies that work well for Western blotting may not necessarily perform optimally for immunofluorescence or flow cytometry. Always review the validation data provided by manufacturers and, when possible, published studies that have successfully used the antibody in your specific application.

What is the typical molecular weight at which NDUFS4 should be detected?

NDUFS4 is expected to be detected at approximately 18-23 kDa on Western blots, consistent with its designation as the 18 kDa subunit of Complex I. Experimental evidence from validated antibodies shows detection at approximately 23 kDa in human cell lysates . This molecular weight information is critical for proper interpretation of Western blot results, as detection at significantly different molecular weights may indicate non-specific binding, post-translational modifications, or degradation products. When running Western blots for NDUFS4, researchers should include appropriate positive controls such as heart tissue or mitochondria-rich cell lysates, where NDUFS4 is abundantly expressed. Detection of bands at unexpected molecular weights should be critically evaluated to determine whether they represent specific NDUFS4 detection or potential cross-reactivity with other proteins.

What species reactivity is commonly available for NDUFS4 antibodies?

Commercial NDUFS4 antibodies are typically validated for detection of human, mouse, and rat NDUFS4 proteins . This cross-species reactivity reflects the high conservation of NDUFS4 across mammalian species, which is consistent with its fundamental role in mitochondrial function. When planning experiments with other species, researchers should carefully evaluate sequence homology between the immunogen used to generate the antibody and the target protein in their species of interest. For highly conserved proteins like NDUFS4, antibodies may work in additional species beyond those explicitly validated by manufacturers, but this requires empirical verification. Always perform proper validation when using antibodies in non-validated species, including positive and negative controls to confirm specificity.

What controls should be included when using NDUFS4 antibodies?

Proper experimental controls are essential for validating NDUFS4 antibody specificity. At minimum, researchers should include:

• Positive controls: Tissues or cells known to express NDUFS4 (e.g., heart tissue, mitochondria-rich cells)

• Negative controls: Ideally, NDUFS4 knockout cells or tissues when available

• Loading controls: Appropriate housekeeping proteins (e.g., GAPDH) to normalize expression levels

• Isotype controls: For immunohistochemistry or flow cytometry applications

Published validation data for NDUFS4 antibodies commonly includes comparison between wild-type and knockout cell lysates, as demonstrated with HAP1 cells . These genetic knockout controls represent the gold standard for antibody validation as they conclusively demonstrate specificity. When knockout controls are unavailable, researchers should consider alternative validation approaches such as siRNA knockdown or comparing staining patterns with a second antibody targeting a different epitope of NDUFS4.

How does the mechanism of NADH binding and oxidation in Complex I impact experimental design when studying NDUFS4?

Understanding the mechanism of NADH binding and oxidation is crucial when designing experiments to study NDUFS4 function within Complex I. Research has demonstrated that in Complex I, the adenosine moiety of NADH is crucial for binding, while nicotinamide-containing fragments lacking adenosine do not bind effectively . Additionally, hydride transfer and NAD+ dissociation are partially rate-limiting steps in NADH oxidation, with the enzyme balancing transition state energies to prevent any single step from becoming fully rate-limiting . When investigating NDUFS4's role in Complex I assembly and function, researchers should consider how mutations or modifications might affect these kinetic parameters. Experimental designs should incorporate measurements of both NADH binding affinity and oxidation rates to comprehensively assess functional impacts. Additionally, since Complex I balances weak nucleotide binding constants with high nucleotide concentrations, researchers should carefully consider physiological nucleotide concentrations in their experimental systems to accurately reflect in vivo conditions.

What are the limitations of orthogonal validation methods for NDUFS4 antibodies?

While orthogonal validation methods (comparing antibody staining with RNA expression or bioinformatic predictions) are commonly used to assess antibody specificity, they have important limitations when applied to NDUFS4. Research on antibody validation has indicated that comparing antibody staining to RNA expression may not reliably indicate selectivity, particularly for immunofluorescence applications, with genetic knockout controls providing more definitive evidence of specificity . For NDUFS4, this is particularly relevant as post-transcriptional regulation and protein stability may cause discrepancies between mRNA and protein levels. The Human Protein Atlas project has identified inconsistencies between antibody staining and bioinformatic predictions, requiring subjective comparisons between these data types . For optimal validation of NDUFS4 antibodies, researchers should prioritize genetic approaches (knockout or knockdown) over orthogonal methods when possible, while recognizing that correlative approaches between protein and RNA levels can still provide valuable supporting evidence in the absence of genetic controls.

How can researchers distinguish between direct effects on NDUFS4 versus secondary effects on Complex I assembly?

Distinguishing direct effects on NDUFS4 from secondary effects on Complex I assembly represents a significant experimental challenge. When manipulating NDUFS4 expression or function, researchers should implement a comprehensive approach that includes:

• Assessing NDUFS4 protein levels via validated antibodies

• Measuring Complex I assembly using blue native PAGE

• Evaluating functional activity through NADH:ubiquinone oxidoreductase assays

• Monitoring levels of other Complex I subunits to detect assembly defects

This multi-parameter approach helps differentiate between primary effects on NDUFS4 and downstream consequences for Complex I integrity. Since NDUFS4 is an accessory subunit not directly involved in catalysis , functional defects observed after NDUFS4 manipulation likely reflect disrupted complex assembly or stability rather than direct catalytic inhibition. Time-course experiments can provide additional insights, as primary effects on NDUFS4 should precede secondary changes in complex assembly. Researchers should consider these distinctions when interpreting experimental results and attributing phenotypes to NDUFS4 dysfunction.

What validation experiments should be performed to ensure NDUFS4 antibody specificity?

To ensure NDUFS4 antibody specificity, researchers should implement a hierarchical validation strategy with increasing levels of stringency:

Notably, research has demonstrated that within the immunofluorescence application (which often shows poorer performance), antibodies are presented without any validation data 87.5% of the time . This highlights the critical importance of performing and reporting proper validation. When publishing research using NDUFS4 antibodies, detailed methodology and validation data should be included to enhance reproducibility and credibility of findings.

How does batch-to-batch variability affect NDUFS4 antibody performance?

Batch-to-batch variability represents a significant challenge for researchers using NDUFS4 antibodies. As biological reagents, antibodies can exhibit performance differences between production lots, potentially compromising experimental reproducibility. For polyclonal NDUFS4 antibodies, this variability is typically more pronounced than for monoclonal alternatives. Each new antibody batch should undergo validation to confirm:

• Specificity for the target at the expected molecular weight

• Consistent signal-to-noise ratio compared to previous lots

• Reproducible performance in the specific application

• Similar optimal working dilutions

To mitigate variability impacts, researchers should maintain detailed records of antibody lot numbers used in experiments and consider purchasing sufficient quantities of a single validated lot for long-term studies. When lot changes are unavoidable, side-by-side comparisons between old and new lots should be performed to establish equivalence before proceeding with critical experiments. This approach helps distinguish genuine biological variation from technical artifacts introduced by reagent inconsistency.

What factors influence the selection between monoclonal and polyclonal NDUFS4 antibodies?

The choice between monoclonal and polyclonal NDUFS4 antibodies should be guided by the specific research application and experimental goals:

How should researchers design experiments to study NDUFS4 in the context of mitochondrial dysfunction?

When designing experiments to investigate NDUFS4 in mitochondrial dysfunction contexts, researchers should implement a multi-layered approach:

• Expression analysis: Quantify NDUFS4 levels using validated antibodies via Western blot and/or immunohistochemistry

• Localization studies: Determine subcellular distribution through fractionation and immunofluorescence

• Functional assessments: Measure Complex I activity using NADH:ubiquinone oxidoreduction assays

• Assembly analysis: Evaluate Complex I assembly state using blue native PAGE

• Mitochondrial function metrics: Assess membrane potential, oxygen consumption, and ATP production

These parameters should be examined across relevant experimental conditions, such as oxidative stress induction, energy substrate manipulation, or genetic models of disease. Since NDUFS4 is an accessory subunit not directly involved in catalysis , changes in its expression or localization may reflect adaptive responses to mitochondrial stress rather than direct functional alterations. Temporal dynamics are particularly important, as early changes in NDUFS4 may precede detectable functional deficits in Complex I activity. Researchers should carefully design time-course experiments to capture these potential sequential alterations in mitochondrial structure and function.

What are the optimal sample preparation methods for detecting NDUFS4 in different applications?

Sample preparation critically influences NDUFS4 detection across different experimental applications:

For Western blot applications, detection is typically observed at approximately 23 kDa . Sample preparation should aim to preserve mitochondrial integrity while effectively extracting membrane-associated proteins. For tissue samples, heart tissue represents an excellent positive control due to high mitochondrial content . When preparing samples from tissues with lower mitochondrial content, enrichment through differential centrifugation may improve detection sensitivity. All samples should be processed with appropriate protease inhibitors to prevent degradation of mitochondrial proteins during preparation.

How can researchers effectively use NDUFS4 antibodies in co-immunoprecipitation studies of Complex I assembly?

Co-immunoprecipitation (co-IP) studies using NDUFS4 antibodies require careful consideration of Complex I's membrane-embedded nature and multi-subunit composition. Effective co-IP protocols should include:

• Gentle solubilization using mild detergents (0.5-1% digitonin or 1% n-dodecyl β-D-maltoside) to preserve protein-protein interactions

• Sufficient antibody validation to ensure specificity before attempting co-IP

• Pre-clearing steps to reduce non-specific binding

• Appropriate negative controls (isotype antibodies, knockout samples when available)

• Validation of interaction partners through reciprocal co-IP when possible

For NDUFS4 specifically, researchers should recognize that as an accessory subunit, it may not interact directly with all Complex I components. Successful co-IP experiments typically identify interactions with nearby subunits and assembly factors rather than the entire complex. Researchers might consider crosslinking approaches to stabilize transient interactions, particularly when studying dynamic assembly processes. Additionally, native PAGE followed by second-dimension SDS-PAGE can provide complementary information about NDUFS4 incorporation into assembly intermediates when combined with immunoblotting using validated antibodies.

What are common pitfalls in NDUFS4 antibody-based experiments and how can they be addressed?

Researchers frequently encounter specific challenges when working with NDUFS4 antibodies:

A critical but often overlooked issue is the failure to validate antibodies for specific applications. Research indicates that for immunofluorescence applications, antibodies are presented without validation data 87.5% of the time . For NDUFS4 detection, researchers should always verify antibody performance in their specific experimental system before conducting critical experiments. This validation should include positive controls (tissues/cells with known NDUFS4 expression) and, ideally, negative controls (NDUFS4 knockout or knockdown samples).

How can researchers reconcile conflicting data between antibody-based detection and functional assays of Complex I?

Discrepancies between antibody-based detection of NDUFS4 and functional Complex I assays are not uncommon and require systematic troubleshooting:

• Verify antibody specificity using genetic approaches (knockout/knockdown) to ensure accurate NDUFS4 detection

• Consider post-translational modifications that might affect antibody recognition but not protein function

• Assess Complex I assembly state, as NDUFS4 might be present but not incorporated into functional complexes

• Evaluate compensatory mechanisms where other subunits might partially rescue function despite NDUFS4 alterations

• Examine temporal dynamics, as protein levels and functional changes may not occur simultaneously

Since NDUFS4 is an accessory subunit believed not to be directly involved in catalysis , its presence may not always correlate perfectly with Complex I activity. The primary role of NDUFS4 in complex stability means that modest reductions might not immediately impact function, while its complete absence would significantly compromise complex assembly. When encountering discrepancies, researchers should employ multiple complementary approaches (e.g., blue native PAGE, activity assays, superoxide production measurements) to comprehensively characterize Complex I status beyond simple protein detection.

What strategies can improve reproducibility when using NDUFS4 antibodies across different laboratories?

Enhancing reproducibility of NDUFS4 antibody-based research across laboratories requires systematic standardization:

• Detailed methodology reporting: Include complete antibody information (manufacturer, catalog number, lot number, dilution, incubation conditions)

• Validation documentation: Provide evidence of antibody specificity in the specific application and experimental system

• Reference sample sharing: Distribute common positive and negative control samples between collaborating laboratories

• Protocol standardization: Develop and share detailed protocols, including buffer compositions and incubation parameters

• Blind sample analysis: Implement blinded analysis to reduce experimenter bias

The reproducibility crisis has particularly affected antibody-based research, with poor antibody selection and insufficient validation identified as major contributors . For NDUFS4 research specifically, laboratories should establish consensus on validated antibody clones for particular applications and sample types. When possible, antibody characterization data should be shared through community resources or repositories. Additionally, researchers should consider publishing detailed antibody validation protocols as supplementary materials, enabling others to verify reagent performance in their own experimental systems before proceeding with complex experiments.

How is the field of NDUFS4 antibody development and validation likely to evolve?

The future of NDUFS4 antibody technology and validation will likely be shaped by several emerging trends in antibody science. Development of recombinant antibodies with precisely defined binding characteristics will gradually replace traditional polyclonal antibodies, enhancing reproducibility across studies. As genetic editing technologies become more accessible, validation using knockout models will become standard practice rather than exceptional. Community-based validation initiatives, similar to those established for other protein targets, may emerge to systematically evaluate commercially available NDUFS4 antibodies across applications and experimental systems. These collaborative efforts will likely establish consensus guidelines for antibody selection and validation specific to mitochondrial research. Additionally, increased awareness of reproducibility challenges will drive more rigorous reporting standards in publications, with journals potentially requiring more comprehensive antibody validation data before acceptance. This evolution will ultimately enhance the reliability of NDUFS4 research, enabling more sophisticated investigations into its role in mitochondrial function and disease.

What are emerging applications of NDUFS4 antibodies in mitochondrial disease research?

NDUFS4 antibodies are finding new applications in mitochondrial medicine as technological advances enable more sophisticated analyses. These include:

• Single-cell profiling of NDUFS4 expression in heterogeneous tissues to identify vulnerable cell populations in mitochondrial diseases

• Proximity labeling approaches to map the NDUFS4 interactome during complex assembly and stress responses

• Correlative light and electron microscopy to precisely localize NDUFS4 within mitochondrial ultrastructure

• Therapeutic development, using NDUFS4 antibodies to monitor treatment efficacy in models of mitochondrial dysfunction

• Biomarker development, exploring NDUFS4 detection in accessible patient samples as potential diagnostic or prognostic indicators